COLL
NASDAQ · Pharmaceuticals
Collegium Pharmaceutical Inc
$35.36
+0.74 (+2.14%)
Financial Highlights (FY 2026)
Revenue
637.67M
Net Income
51.36M
Gross Margin
59.3%
Profit Margin
8.1%
Rev Growth
+18.9%
D/E Ratio
2.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 35.1% | 35.1% |
| Operating Margin | 21.0% | 18.9% | 21.2% | 20.6% |
| Profit Margin | 8.1% | 7.7% | 14.1% | 14.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 637.67M | 536.13M | 486.77M | 543.10M |
| Gross Profit | 378.46M | 318.19M | 171.09M | 190.89M |
| Operating Income | 133.66M | 101.14M | 103.40M | 112.13M |
| Net Income | 51.36M | 38.86M | 68.71M | 79.42M |
| Gross Margin | 59.3% | 59.3% | 35.1% | 35.1% |
| Operating Margin | 21.0% | 18.9% | 21.2% | 20.6% |
| Profit Margin | 8.1% | 7.7% | 14.1% | 14.6% |
| Rev Growth | +18.9% | +18.9% | +18.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 396.22M | 396.22M | 505.83M | 501.20M |
| Total Equity | 147.69M | 147.69M | 1.10B | 1.07B |
| D/E Ratio | 2.68 | 2.68 | 0.46 | 0.47 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 137.10M | 109.51M | 134.63M | 134.48M |
| Free Cash Flow | — | — | 97.48M | 99.20M |